1353900-92-1,MFCD30747902
Catalog No.:AA01E6J6

1353900-92-1 | Pibrentasvir

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$19.00   $13.00
- +
5mg
98%
in stock  
$34.00   $24.00
- +
10mg
≥98%
in stock  
$55.00   $38.00
- +
25mg
98%
in stock  
$91.00   $64.00
- +
50mg
≥98%
in stock  
$176.00   $123.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA01E6J6
Chemical Name:
Pibrentasvir
CAS Number:
1353900-92-1
Molecular Formula:
C57H65F5N10O8
Molecular Weight:
1113.1802
MDL Number:
MFCD30747902
SMILES:
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1[nH]c2c(n1)cc(c(c2)[C@H]1CC[C@@H](N1c1cc(F)c(c(c1)F)N1CCC(CC1)c1ccc(cc1)F)c1cc2[nH]c(nc2cc1F)[C@@H]1CCCN1C(=O)[C@H]([C@H](OC)C)NC(=O)OC)F)[C@H](OC)C
Properties
Computed Properties
 
Complexity:
2000  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
8  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
80  
Hydrogen Bond Acceptor Count:
17  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0  
Rotatable Bond Count:
17  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
7.4  

Downstream Synthesis Route

[1]Wagner,Rolf;Randolph,JohnT.;Patel,SachinV.;Nelson,Lissa;Matulenko,MarkA.;Keddy,Ryan;Pratt,JohnK.;Liu,Dachun;Krueger,A.Chris;Donner,PamelaL.;Hutchinson,DouglasK.;Flentge,Charles;Betebenner,David;Rockway,Todd;Maring,ClarenceJ.;Ng,TeresaI.;Krishnan,Preethi;Pilot-Matias,Tami;Collins,Christine;Panchal,Neeta;Reisch,Thomas;Dekhtyar,Tatyana;Mondal,Rubina;Stolarik,DeanneF.;Gao,Yi;Gao,Wenqing;Beno,DavidA.;Kati,WarrenM.[JournalofMedicinalChemistry,2018,vol.61,#9,p.4052-4066]

[2]Wagner,Rolf;Randolph,JohnT.;Patel,SachinV.;Nelson,Lissa;Matulenko,MarkA.;Keddy,Ryan;Pratt,JohnK.;Liu,Dachun;Krueger,A.Chris;Donner,PamelaL.;Hutchinson,DouglasK.;Flentge,Charles;Betebenner,David;Rockway,Todd;Maring,ClarenceJ.;Ng,TeresaI.;Krishnan,Preethi;Pilot-Matias,Tami;Collins,Christine;Panchal,Neeta;Reisch,Thomas;Dekhtyar,Tatyana;Mondal,Rubina;Stolarik,DeanneF.;Gao,Yi;Gao,Wenqing;Beno,DavidA.;Kati,WarrenM.[JournalofMedicinalChemistry,2018,vol.61,#9,p.4052-4066]

40224-39-3    1353900-92-1   
(S)-(5-((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)-5-(5-fluoro-2-((S)-1-((25,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazol-6-yl)pyrrolidin-2-yl)-6-fluoro-2-((S)-1-((2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazol-1-yl)methyl-2-((tert-butoxycarbonyl)amino)-3-methylbutanoate 
 
(2S,2’S)-((S,S,R)-5,5‘-((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-2-((S)-1-((2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazole-5,1-diyl))bis(methylene)bis(2-((tert-butoxycarbonyl)amino)-3-methylbutanoate) 
 
(S)-(5-((2R,5R)-5-(1-((((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoyl)oxy)methyl)-5-fluoro-2-((S)-1-((2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazol-6-yl)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidin-2-yl)-6-fluoro-2-((S)-1-((2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazol-1-yl)methyl-2-((tert-butoxycarbonyl)amino)-3-methylbutanoate 

[1]Patent:WO2018/93717,2018,A1.Locationinpatent:Paragraph0079;0081;0083

[1]DeGoey,DavidA.;Greszler,StephenN.;Hartung,John;Ji,Jianguo;Klix,RussellC.;Randolph,JohnT.;Shelat,BhadraH.;Voight,EricA.;Waters,JanE.[ChemicalScience,2021,vol.12,#29,p.10076-10082]

Literature

Title: In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.

Journal: Antimicrobial agents and chemotherapy 20170501

Title: Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles.

Journal: Journal of virology 20080801

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1353900-92-1
Tags:1353900-92-1 Molecular Formula|1353900-92-1 MDL|1353900-92-1 SMILES|1353900-92-1 Pibrentasvir
Catalog No.: AA01E6J6
1353900-92-1,MFCD30747902
1353900-92-1 | Pibrentasvir
Pack Size: 1mg
Purity: 98%
in stock
$19.00 $13.00
Pack Size: 5mg
Purity: 98%
in stock
$34.00 $24.00
Pack Size: 10mg
Purity: ≥98%
in stock
$55.00 $38.00
Pack Size: 25mg
Purity: 98%
in stock
$91.00 $64.00
Pack Size: 50mg
Purity: ≥98%
in stock
$176.00 $123.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA01E6J6
Chemical Name: Pibrentasvir
CAS Number: 1353900-92-1
Molecular Formula: C57H65F5N10O8
Molecular Weight: 1113.1802
MDL Number: MFCD30747902
SMILES: COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1[nH]c2c(n1)cc(c(c2)[C@H]1CC[C@@H](N1c1cc(F)c(c(c1)F)N1CCC(CC1)c1ccc(cc1)F)c1cc2[nH]c(nc2cc1F)[C@@H]1CCCN1C(=O)[C@H]([C@H](OC)C)NC(=O)OC)F)[C@H](OC)C
Properties
Complexity: 2000  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 8  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 80  
Hydrogen Bond Acceptor Count: 17  
Hydrogen Bond Donor Count: 4  
Isotope Atom Count: 0  
Rotatable Bond Count: 17  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 7.4  
Downstream Synthesis Route
1292836-16-8    1353900-92-1 

[1]Wagner,Rolf;Randolph,JohnT.;Patel,SachinV.;Nelson,Lissa;Matulenko,MarkA.;Keddy,Ryan;Pratt,JohnK.;Liu,Dachun;Krueger,A.Chris;Donner,PamelaL.;Hutchinson,DouglasK.;Flentge,Charles;Betebenner,David;Rockway,Todd;Maring,ClarenceJ.;Ng,TeresaI.;Krishnan,Preethi;Pilot-Matias,Tami;Collins,Christine;Panchal,Neeta;Reisch,Thomas;Dekhtyar,Tatyana;Mondal,Rubina;Stolarik,DeanneF.;Gao,Yi;Gao,Wenqing;Beno,DavidA.;Kati,WarrenM.[JournalofMedicinalChemistry,2018,vol.61,#9,p.4052-4066]

[2]Wagner,Rolf;Randolph,JohnT.;Patel,SachinV.;Nelson,Lissa;Matulenko,MarkA.;Keddy,Ryan;Pratt,JohnK.;Liu,Dachun;Krueger,A.Chris;Donner,PamelaL.;Hutchinson,DouglasK.;Flentge,Charles;Betebenner,David;Rockway,Todd;Maring,ClarenceJ.;Ng,TeresaI.;Krishnan,Preethi;Pilot-Matias,Tami;Collins,Christine;Panchal,Neeta;Reisch,Thomas;Dekhtyar,Tatyana;Mondal,Rubina;Stolarik,DeanneF.;Gao,Yi;Gao,Wenqing;Beno,DavidA.;Kati,WarrenM.[JournalofMedicinalChemistry,2018,vol.61,#9,p.4052-4066]

40224-39-3    1353900-92-1   
(S)-(5-((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)-5-(5-fluoro-2-((S)-1-((25,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazol-6-yl)pyrrolidin-2-yl)-6-fluoro-2-((S)-1-((2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazol-1-yl)methyl-2-((tert-butoxycarbonyl)amino)-3-methylbutanoate 
 
(2S,2’S)-((S,S,R)-5,5‘-((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis(6-fluoro-2-((S)-1-((2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazole-5,1-diyl))bis(methylene)bis(2-((tert-butoxycarbonyl)amino)-3-methylbutanoate) 
 
(S)-(5-((2R,5R)-5-(1-((((S)-2-((tert-butoxycarbonyl)amino)-3-methylbutanoyl)oxy)methyl)-5-fluoro-2-((S)-1-((2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazol-6-yl)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidin-2-yl)-6-fluoro-2-((S)-1-((2S,3R)-3-methoxy-2-((methoxycarbonyl)amino)butanoyl)pyrrolidin-2-yl)-1H-benzodimidazol-1-yl)methyl-2-((tert-butoxycarbonyl)amino)-3-methylbutanoate 

[1]Patent:WO2018/93717,2018,A1.Locationinpatent:Paragraph0079;0081;0083

24424-99-5    1353900-92-1    2641244-17-7 

[1]DeGoey,DavidA.;Greszler,StephenN.;Hartung,John;Ji,Jianguo;Klix,RussellC.;Randolph,JohnT.;Shelat,BhadraH.;Voight,EricA.;Waters,JanE.[ChemicalScience,2021,vol.12,#29,p.10076-10082]

Literature fold

Title: In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.

Journal: Antimicrobial agents and chemotherapy20170501

Title: Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles.

Journal: Journal of virology20080801

Building Blocks More >
32986-66-6
32986-66-6
(2E)-3-(pyridin-4-yl)prop-2-enal, E
AA01E6XT | MFCD18384440
215247-95-3
215247-95-3
Pigment Violet 23
AA01E72A | MFCD00281166
312914-49-1
312914-49-1
2-(3-methoxyphenyl)-2,3-dihydro-1H-isoindol-1-imine
AA01E78E | MFCD00993408
2095410-74-3
2095410-74-3
5-chloro-2-cyclopropyl-2,3-dihydro-1lambda6,2-thiazole-1,1,3-trione
AA01E7BF | MFCD30631642
2126159-46-2
2126159-46-2
1-{5H,6H,7H,8H-imidazo[1,2-a]pyrimidin-3-yl}ethan-1-one
AA01E7EE | MFCD31381364
311797-29-2
311797-29-2
ethyl 2,2-difluoro-2-(1,3-thiazol-2-yl)acetate
AA01E7HV | MFCD31559117
1520934-09-1
1520934-09-1
1-(thietan-3-yl)propan-1-ol
AA01E7KQ | MFCD30751388
2138155-71-0
2138155-71-0
4-(chloromethyl)-3,5-dimethylbenzonitrile
AA01E7NS | MFCD31421376
1227588-69-3
1227588-69-3
2-(4-Hydroxypyridin-3-yl)acetic acid
AA01E7QJ | MFCD16609392
90345-37-2
90345-37-2
6-hydroxy-5-(propan-2-yl)-3,4-dihydropyrimidin-4-one
AA01E7VR | MFCD22690696
Submit
© 2017 AA BLOCKS, INC. All rights reserved.